Compound preparation having anti-tumor action

Abstract

The invention provides a compound preparation having an anti-tumor action. The compound preparation comprises therapeutically effective amounts of ingredient A, ingredient B, ingredient C and a pharmaceutically acceptable carrier; or mixture of the ingredient A, the ingredient B and the ingredient C; or a capsule taking the mixture of the ingredient B and the ingredient C as restricted substances; the ingredient A is enteric coating particles of dipyridamole and is formed by dipyridamole enteric particles and coating layers for packing the dipyridamole enteric particles; the ingredient B is ubenimex adhesion particles taking insoluble cellulose and biological adhesive materials as carriers; and the ingredient C is dexamethasone with a particle size of 100-200 nm. The compound preparation having the anti-tumor action formed by the three compositions can reach the peak value in blood at a higher speed, and can remain longer effective concentration time respectively, so that the requirement of clinical application can be met.

Description

technical field [0001] The invention relates to an antitumor drug, in particular to a compound preparation with dipyridamole, ubenimex and dexamethasone as active ingredients. Background technique [0002] Malignant tumor is a common disease that seriously threatens human health. In today's world, there is an urgent need for anti-tumor drugs. According to the data in 2007, there were 12 million newly diagnosed cancer patients in the world, and 7.6 million people died of cancer. According to the data of the top ten disease mortality and cause of death of urban and rural residents in my country in 2007, the cause of death of malignant tumors in my country's urban and rural areas is 28.5% and 24.8%, respectively, ranking first in the cause of death. WHO data It shows that cancer is the main cause of death, and cancer patients will continue to increase. Cancer as the cause of death accounted for 13.8% in 2008, 15.2% in 2015, and 17.6% in 2030. [0003] In clinical cancer trea...

AI Technical Summary

Problems solved by technology

The dissolution of tablets and sustained-release capsules on the market is carried out with hydrochloric acid (9→1000) according to the Pharmacopoeia. Since dipyridamole is dissolved in acidic medium, but when it is transported from the stomach to the intestine, the intestinal juice The pH is alkaline, dipyridamole will be precipitated, and the precipitated dipyridamole will be affected by many factors such as food and preparation excipients, resulting in great differences in oral absorption

Especially for the 1, 3, and 7-hour release of dipyridamole sustained-release capsules, the dissolution medium is also an acidic medium. It is well known that the general capsule stays in the stomach for 2 hours, and then enters the intestinal tract. The release under acidic conditions is inconsistent, which may affect its bioavailability

The inventors found in the research that dipyridamole is not uniformly dispersed when it is dissolved in acid and precipitated in alkali, and there are phenomena such as aggregation, that is, the particle size of dipyridamole may be very large when it is precipitated, thereby causing Affect the absorption of drugs through the mucosa. Therefore, the blood concentration of the current oral preparations fluctuates greatly, and it is difficult for ordinary preparations to maintain a relatively stable and effective concentration for inhibiting platelet aggregation.

Images